AFP mRNA在监测肝癌转移复发上的研究现况  

AFP mRNA monitoring in hepatocellular carcinoma with metastasis and relapse

作　　者：邱谢武[1] 于聪慧[1] 

机构地区：[1]中国人民解放军北京军区总医院肝胆外科,北京100700

出　　处：《国际外科学杂志》2011年第10期697-700,共4页International Journal of Surgery

基　　金：首都医学发展科研基金（No.2007-3024）

摘　　要：手术切除是目前治疗肝癌的最佳途径，但术后肿瘤的转移复发严重制约了手术的疗效。肝癌的转移和复发不但严重威胁着人们的健康，而且给患者家庭以及社会都带来了沉重的负担。当前公认肝癌的诊断标志物为AFP，但其特异性不高，且AFP的生物学特性使其不能作为监测肝癌转移复发的标志物。随着基因技术的发展，人们发现AFP的前体AFPmRNA可作为监测肝癌转移复发的标志物，本文就此作一综述。Surgical resection is the best way to treat liver cancer, but the effect of tumor with post-opera- tional metastasis and relapse post-operational was severely restricted. Metastasis and relapse of hepatoeellular carcinoma（HCC） is not only a serious threat to people＇s health, but also a heavy burden to the family and society. The recognized marker of HCC now is AFP, but the lack of specificity and the bionomics limit it to be the marker of metastasis and relapse of HCC. With the developing of gene technology, AFP mRNA, the prosoma of AFP, is used as a marker of monitoring the metastasis and relapse of HCC. We review AFP mRNA monitoring in HCC with metastasis and relapse.

关 键 词：AFP MRNA 肝癌 转移 复发 

分 类 号：R735.7[医药卫生—肿瘤]